Cellebrite DI (NASDAQ:CLBT) Price Target Raised to $22.00

Cellebrite DI (NASDAQ:CLBT) had its target price upped by DA Davidson from $20.00 to $22.00 in a research note issued to investors on Thursday morning,Benzinga reports. DA Davidson currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.80.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $16.01 on Thursday. The firm has a market capitalization of $3.99 billion, a P/E ratio of 57.18, a PEG ratio of 1.98 and a beta of 1.18. Cellebrite DI has a one year low of $11.02 and a one year high of $19.98. The business has a fifty day moving average price of $14.55 and a 200-day moving average price of $14.11.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas E. Hogan sold 103,188 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the sale, the chief executive officer owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. CWM LLC boosted its position in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. SkyView Investment Advisors LLC boosted its position in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after buying an additional 970 shares during the period. Alamea Verwaltungs GmbH grew its stake in shares of Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock valued at $444,000 after buying an additional 1,018 shares during the last quarter. Finally, Pacer Advisors Inc. grew its stake in shares of Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after buying an additional 1,238 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.